Publication:

A prospective identification and mechanistic evaluation of clinically significant drug–drug interactions in chronic kidney disease patients using the Micromedex® database

Background Chronic kidney disease (CKD) patients are highly susceptible to drug–drug interactions (DDIs) due to polypharmacy and altered pharmacokinetics. To prospectively identify and characterize clinically significant DDIs in CKD patients using a standardized database approach.

Methods A prospective observational study was conducted in 380 CKD patients (stages 1–5). Drug–drug interactions were identified using the Micromedex® database. Clinically significant DDIs were predefined as interactions classified as major or moderate severity or those requiring clinical intervention such as dose adjustment, monitoring, or drug avoidance. Interactions were categorized by severity and mechanism (pharmacokinetic/pharmacodynamic), including cytochrome P450 (CYP) involvement.

Results A total of 61 clinically significant DDIs were identified, including 21 major, 28 moderate, and 12 minor interactions. Major DDIs were predominantly pharmacodynamic and associated with bleeding, nephrotoxicity, electrolyte imbalance, and cardiac conduction abnormalities. Pharmacokinetic interactions commonly involved CYP3A4, followed by CYP2D6, CYP2C9, and CYP2C19 enzymes.

Conclusion Clinically significant DDIs are common in CKD patients and can be systematically identified using standardized tools such as Micromedex®. Most interactions are predictable and manageable through monitoring, dose adjustment, or avoidance strategies.